The purpose of this study is to evaluate the safety and efficacy of traditional Chinese medicine in the treatment of adolescent sleep disorders and the effect of sleeping pills withdrawal.

开始日期2023-12-22

申办/合作机构

南京医科大学第一附属医院

NCT06467851 / CompletedN/AIIT

An Interventional Clinical Study to Investigate the Effect of Oral Administration of Suanzaoren Decoction and Huanglian Wendan Decoction on Human Biorhythms in Patients With Insomnia

The purpose of this study was to examine the impact of Chinese medicine on melatonin levels in patients with insomnia

开始日期2023-08-31

申办/合作机构

南京医科大学第一附属医院

ChiCTR2400085804 / CompletedN/AIIT

Clinical observation on the therapeutic effect of Huanglian Wendan decoction combined with transcranial magnetic stimulation on post-stroke depression

开始日期2022-11-01

申办/合作机构-

100 项与黄连温胆汤相关的临床结果

登录后查看更多信息

100 项与黄连温胆汤相关的转化医学

登录后查看更多信息

100 项与黄连温胆汤相关的专利（医药）

登录后查看更多信息

项与黄连温胆汤相关的文献（医药）

2023-10-19·The international journal of neuropsychopharmacology

A Synthetic External Control Study Comparing the Clinical Efficacy of Wendan Decoction and 19 Antidepressants.

Article

作者: Zheng, Qingshan ; Lv, Yinghua ; Yang, Yuting ; Li, Lujin ; Chen, Rui ; Tan, Hongsheng ; Li, Caixia

BACKGROUNDWendan decoction (WDD) has been used as a treatment for depression in China since the Tang Dynasty. However, high-quality evidence for this is lacking. This study proposed a novel synthetic external control method to evaluate its clinical efficacy.METHODSWe searched public databases for clinical trials of WDD for major depression. The rate of change of the Hamilton Depression Scale score from baseline was used as an efficacy indicator, and a model-based meta-analysis was performed to analyze the clinical efficacy of WDD. To establish a reference standard for efficacy, the antidepressant efficacy distributions of a placebo and 19 antidepressants were virtually synthesized based on the same conditions as the clinical trial characteristics of WDD.RESULTSThis study included 5 clinical trials with 177 participants. WDD showed a slow onset, with a time to reach the maximum effect of 9.71 weeks. At 8 weeks, the rate of change in the Hamilton Depression Scale score from baseline was 66.4% (95% CI = 62.3%-70.3%) in the WDD group. The pure effect value of WDD, after deducting the placebo effect, was 26.9% (95%CI = 23.0%-30.9%), which was comparable with 5 types of antidepressants and significantly higher than the others.CONCLUSIONThe proposed external synthetic control method provides a solution to the bottleneck problem of clinical efficacy evaluation in real-world research on traditional Chinese medicine. WDD has high clinical development value for the treatment of depression, and large-scale randomized controlled trials are recommended to confirm its antidepressant effect.

2012-05-25·Neural regeneration research2区 · 医学

Wendan decoction improves learning and memory deficits in a rat model of schizophrenia.

2区 · 医学

ArticleOA

作者: Yang, Cuiping ; Yang, Yanping ; Zhou, Zhigang ; Yang, Xiaojin ; Wan, Hongjiao ; Cai, Changchun ; Liu, Jianhua ; Ye, Heping

An experimental model of schizophrenia was established using dizocilpine (MK-801). Rats were intragastrically administered with Wendan decoction or clozapine for 21 days prior to establishing the model. The results revealed that the latency of schizophrenia model rats to escape from the hidden platform in the Morris water maze was significantly shortened after administration of Wendan decoction or clozapine. In addition, the treated rats crossed the platform significantly more times than the untreated model rats. Moreover, the rate of successful long-term potentiation induction in the Wendan decoction group and clozapine group were also obviously increased compared with the model group, and the population spike peak latency was significantly shortened. These experimental findings suggest that Wendan decoction can improve the learning and memory ability of schizophrenic rats to the same extent as clozapine treatment.

Biological Procedures Online

Effects and Mechanisms of the Xianhecao-Huanglian Drug Pair on Autophagy-Mediated Intervention in Acute Inflammatory Bowel Disease via the JAK2/STAT3 Pathway

Article

作者: Shen, Xinling ; Peng, Haiyan ; He, Yaping

AbstractTo explore the effects and mechanisms of the Xianhecao-Huanglian drug pair on autophagy-mediated intervention in acute inflammatory bowel disease (IBD) via the JAK2/STAT3 pathway. The study examined the underlying mechanisms of action of Xianhecao (APL) and Huanglian (CR) using a mouse model of dextran sodium sulfate (DSS)-induced acute inflammatory bowel disease (IBD) and in an in vitro model of IBD induced by lipopolysaccharide (LPS). The assessment of the therapeutic efficacy of the Xianhecao-Huanglian drug combination in a mouse model of IBD caused by DSS included the following parameters: Assessment of weight loss or gain. Measurement of the disease activity index (DAI). Assessment of histological damage. Determination of organ index. Measurement of colon length. Ascertain the levels of inflammatory cytokines in the intestinal tissues and serum of mice. Immunohistochemistry (IHC) for the measurement of tight junction protein concentrations in the colon mucosa, including ZO-1, claudin-1, and occludin. Measurement of mucin levels, specifically Mucin 2 (Muc2). Hematoxylin and eosin (HE) staining for the observation of histopathological alterations in colonic tissues. Examining the effect on goblet cells using periodic acid-Schiff (PAS) labeling. Application of Western blot and immunofluorescence techniques for the detection of autophagy-related markers in colonic tissues and proteins associated with the JAK2/STAT3 pathway. A cell inflammation model of IBD was induced through LPS stimulation, and a serum containing the Xianhecao-Huanglian drug pair (referred to as ACHP-DS) was formulated. Cell viability, anti-proinflammatory cytokines, tight junction proteins, mucins, autophagy-related markers, and the JAK2/STAT3 signaling pathway were assessed. The Xianhecao-Huanglian drug pair significantly ameliorated the symptoms and survival quality of acute IBD mice, reducing the disease activity index score, raising MUC2 secretion and tight junction protein expression to improve the integrity of the intestinal barrier, and preserving goblet cell function; thus, protecting the intestines. It effectively restrained triggering the signaling pathway that involves JAK2 and STAT3, leading to the suppression of inflammation and amelioration of colonic inflammation damage. Additionally, it induced autophagy in mouse colonic tissues.The in vitro experiments demonstrated that the Xianhecao-Huanglian drug combination enhanced the viability of LOVO and NCM460 cells when exposed to LPS stimulation. Furthermore, it suppressed the production of inflammatory cytokines such as IL-6, IL-1β, as well as TNF-α, whilst increasing the production of IL-10, ZO-1, along with MUC2. These effects collectively led to the alleviation of inflammation and the restoration of mucosal integrity. The results were consistent with what was shown in the in vivo trial. Moreover, the medication demonstrated effectiveness in reducing JAK2 along with STAT3 phosphorylation levels in the LPS-induced inflammatory model of IBD cells. The intervention with either the Xianhecao-Huanglian drug combination-containing serum or the JAK2/STAT3 pathway inhibitor AG490 reversed the pro-inflammatory effects and increased autophagy levels in the LPS-stimulated cells. The Xianhecao-Huanglian drug combination modulates the JAK2/STAT3 pathway, leading to the induction of autophagy, which serves as an intervention for IBD.

项与黄连温胆汤相关的新闻（医药）

2024-02-21

·医药地理

春节吃多消化不良？为您送上节后消食用药指南以及药物院端销售分析

春节期间走亲访友，聚餐频繁，不少人开启了大吃大喝模式，一不小心就导致消化不良，市场上治疗消化不良的药物品种繁多，胃痛、胃胀、胃酸...该如何对症下药呢？在此为大家送上一份节后消食用药指南，为胃肠道减轻负担，更好的投入日常工作生活轨道吧！消化不良是指位于上腹部的胃部及十二指肠一种或一组症状，主要表现为上腹痛、上腹部灼感、餐后饱胀和早饱感或恶心、呕吐及嗳气等。按病因可分为器质性消化不良和功能性消化不良。如果是由某些疾病引起的器质性消化不良，会直接按原发病去诊治。因此，通常提及的“消化不良”为功能性消化不良(functional dyspepsia，FD)。根据《2022中国功能性消化不良诊治专家共识》，FD分为上腹痛综合征（EPS）和餐后不适综合征（PDS）。常用的治疗消化不良的药物可以分为以下几类：1. 抑酸药：这类药物主要用于治疗胃酸过多引起的消化不良，如胃炎、胃溃疡等。常见的抑酸药有质子泵抑制剂(如奥美拉唑、雷贝拉唑等)、H2受体阻滞剂(如雷尼替丁、法莫替丁等)。2. 保护胃黏膜药：这类药物主要用于保护胃黏膜，防止胃酸对胃黏膜的损伤。常见的保护胃黏膜药有铋剂(如胶体铋、枸橼酸铋钾等)、磷酸铝、硫糖铝等。3. 抗胃酸返流药物：减少胃酸返流到食道的药物，主要包括质子泵抑制剂、H2受体拮抗剂以及利福平等。4. 促胃肠动力药：这类药物主要用于增强胃肠蠕动，加快食物的消化和吸收。常见的促胃肠动力药有多潘立酮、莫沙必利等。5. 消化酶制剂：这类药物主要用于帮助食物的消化，尤其是对于消化酶缺乏引起的消化不良。常见的消化酶制剂有胰酶、糖酶、脂肪酶等。6. 益生菌和益生元：调节肠道菌群平衡，改善消化功能，常用的包括乳酸菌、双歧杆菌、菊粉等。7. 中药：中医认为消化不良与脾胃虚弱、湿热内阻等因素有关，因此常用的中药有健脾胃的药物(如六君子汤、香砂六君子汤等)、清热化湿的药物(如黄连温胆汤、三黄片等)等。《2022中国功能性消化不良诊治专家共识》中提到，抑酸药物质子泵抑制剂PPI和H2受体拮抗剂可作为上腹痛综合征（EPS）的首选治疗；胃肠促动药可作为餐后不适综合征（PDS）的首选治疗；中成药治疗对改善功能性消化不良症状有较好的疗效；消化酶可改善功能性消化不良患者的部分症状。此外，我国为上消化道恶性肿瘤高发国家，推荐初诊消化不良患者及时进行胃镜检查。了解了基本的药物分类，消化不良类药物在院端的销售表现如何呢?让我们一探究竟。以下数据来自中国医药工业信息中心的PDB药物综合数据库，欢迎扫描文末二维码试用。据PDB药物综合数据库统计，近3年来，治疗消化不良类药物在院端的销售趋势趋于平稳，2021年全国医院市场销售额为38.51亿元，2022年为37.68亿元，2023年Q1-Q3销售额达到30.27亿元。图1: 2021-2023治疗消化不良药销售额统计数据来源：PDB药物综合数据库-国内院端放大，中国医药工业信息中心按照ATC四级分类统计，中药类、止泻药中的止泻微生物类、酶抑制剂类助消化药稳居TOP3榜单。以2023年前三季度销售额为例统计，其中，中药类销售额达到12.3亿元，占比40.65%；止泻微生物销售额为9.77亿元，占比32.28%；酶抑制剂类助消化药销售额为5.44亿元，占比17.97%。图2: 2021-2023治疗消化不良药不同类别药物销售额数据来源：PDB药物综合数据库-国内院端放大，中国医药工业信息中心统计前三季度每季度的TOP 10销售产品发现，销售冠军来自杭州远大生物制药有限公司的双歧杆菌四联活菌片（商品名：思连康），每季度销售额均突破1亿元，销售额占比＞10%。该产品属于止泻微生物类，用于治疗与肠道菌群失调相关的腹泻、便秘、功能性消化不良，于2020年进入国家医保目录。此外，10款产品中近一半都属于中成药，神曲消食口服液、小儿消积止咳口服液、健胃消食口服液、枳术宽中胶囊均有亮眼的销售表现。图3: 2023 Q1-Q3治疗消化不良药销售额TOP 10产品数据来源：PDB药物综合数据库-国内院端放大，中国医药工业信息中心以上药物的使用需要根据患者的具体病情和医生的建议，不同的人可能需要不同的治疗方案。同时，药物治疗只是治疗消化不良的一部分，患者还需要调整饮食习惯，避免过度饮食，保持良好的生活习惯，多多运动。END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

100 项与黄连温胆汤相关的药物交易

登录后查看更多信息